Title:
癌の治療方法および組成物
Document Type and Number:
Japanese Patent JP6722103
Kind Code:
B2
Abstract:
The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
Inventors:
Sawsec, Laura
Beaulieu, Marie-Ave
Beaulieu, Marie-Ave
Application Number:
JP2016512358A
Publication Date:
July 15, 2020
Filing Date:
May 07, 2014
Export Citation:
Assignee:
Fundacio Privada Instituto Din Vesty Gasio on Collodica de Val-Evron
International Classes:
A61K38/17; A61K38/08; A61P35/00; A61P43/00; C07K14/435; C12N15/00
Foreign References:
| WO2013063560A1 | ||||
| WO2011157713A1 |
Other References:
SOUCEK, L., et al., Design and properties of a Myc derivative that efficiently homodimerizes., Oncogene, 1998, Vol.17, No.19, p.2463-2472
SOUCEK, L., et al., Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis., Cancer Research, 2002, Vol.62, No.12, p.3507-3510
DANG, C.V., et al., Identification of the human c-myc protein nuclear translocation signal., Molecular and Cellular Biology, 1988, Vol.8, No.10, p.4048-4054
SOUCEK, L., et al., Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis., Cancer Research, 2002, Vol.62, No.12, p.3507-3510
DANG, C.V., et al., Identification of the human c-myc protein nuclear translocation signal., Molecular and Cellular Biology, 1988, Vol.8, No.10, p.4048-4054
Attorney, Agent or Firm:
Konno Akio
Minoru Inami
Takeyasu Ito
Keisei Tamura
Minoru Inami
Takeyasu Ito
Keisei Tamura